

Announcement of Website Renewal

Thank you for visiting the PDRadiopharma Inc. website.

We are pleased to announce that our website has been completely renewed.

With this update, we have refreshed the design and improved usability, making it easier to find and access the information you need. We have also added new content for the general public and patients, and we now explain technical topics in a more accessible way through the use of photographs and illustrations.

We will continue to enhance the content and further improve the website to make it even more user-friendly.

We sincerely appreciate your continued support.

About PDRadiopharma

PDRadiopharma, a wholly-owned subsidiary of PeptiDream from 2022, has been providing high-quality radiopharmaceuticals through the research and development, manufacturing, regulatory and sales as a forerunner in the field of radiopharmaceuticals, since it started its business in 1968. Currently PDRadiopharma offers 21 radiodiagnostic products (spanning both SPECT and PET products) and 8 radiotherapeutic products (3 product categories) in Japan. Additionally, PDRadiopharma and PeptiDream are developing a broad pipeline of radiotherapeutics and radiodiagnostics for both the Japan and global markets. For more information about PDRadiopharma, please visit <https://www.pdradiopharma.com/>

Inquiries:
PDRadiopharma Inc.
Contact: Akiko Murakami, General Affairs
Email: s-info-hq@pdradiopharma.com